ObsEva Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 51
Employees
  • Stock Symbol
  • OBSV
Stock Symbol
  • Share Price
  • $1.65
  • (As of Tuesday Closing)

ObsEva General Information

Description

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The company is focused on providing therapeutic solutions for women between the ages of 15 and 49 who suffer from reproductive health conditions that affect their quality of life, ability to conceive or that complicate pregnancy and the health of newborns. The is developing OBE2109 as a novel, oral gonadotropin-releasing hormone, or GnRH, receptor antagonist, for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • Chemin des Aulx, 12
  • Plan-les-Ouates
  • 1228 Geneva
  • Switzerland
+41 022 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ObsEva Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.65 $1.56 $1.08 - $3.58 $136M 82.1M 543K -$0.78

ObsEva Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 118,983 118,983 90,794 103,390
Revenue 0 0 0 0
EBITDA (54,273) (54,273) (79,507) (106,800)
Net Income (58,377) (58,377) (82,966) (108,790)
Total Assets 88,991 88,991 65,447 103,943
Total Debt 26,659 26,659 26,948 27,076
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ObsEva Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ObsEva‘s full profile, request access.

Request a free trial

ObsEva Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therap
Biotechnology
Geneva, Switzerland
51 As of 2021
00000
00000000

0000000

dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000 000000000
Turku, Finland
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
000000000000000
Nouzilly, France
0 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ObsEva Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Forendo Pharma Formerly VC-backed Turku, Finland 00 000.00 000000&0 000.00
000000 Venture Capital-Backed Nouzilly, France 0 000.00 0000000000 0 000.00
0000000 00000000 Corporate Backed or Acquired Brisbane, CA 000 00000 000000&0 00000
0000 0000000000000 Accelerator/Incubator Backed Kingston, Canada 0000000000
000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

ObsEva Patents

ObsEva Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3876943-A2 Compositions and methods for the treatment of estrogen-dependent disorders Pending 07-Nov-2018 0000000000
EP-3873465-A2 Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis Pending 29-Oct-2018 0000000000
CA-3117092-A1 Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis Pending 29-Oct-2018 0000000000
AU-2019373349-A1 Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis Pending 29-Oct-2018 0000000000
AU-2018280741-A1 Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss Pending 05-Jun-2017 A61P15/00
To view ObsEva’s complete patent history, request access »

ObsEva Executive Team (20)

Name Title Board Seat Contact Info
Brian O'Callaghan Chief Executive Officer & Board Member
William Brown Chief Financial Officer, Finance
Katja Bührer Chief Strategy Officer
Fabien de Ladonchamps Chief Administrative Officer, Administration
Jean-Pierre Gotteland Ph.D Chief Scientific Officer & Head of R&D
You’re viewing 5 of 20 executive team members. Get the full list »

ObsEva Board Members (16)

Name Representing Role Since
Anne Vanlent Self Board Member 000 0000
Annette Clancy Self Board Member 000 0000
Brian O'Callaghan ObsEva Chief Executive Officer & Board Member 000 0000
Catarina Edfjall ObsEva Board Member 000 0000
Edward Mathers Self Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

ObsEva Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ObsEva Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ObsEva‘s full profile, request access.

Request a free trial